Texas A&M study explores microRNAs to slow lung cancer
Bottom line
Texas A&M researchers have identified two naturally occurring microRNAs, miR-15a and miR-16, as potential brakes on non-small cell lung cancer growth, adding new detail to how these small RNA molecules may restore disrupted cellular control in tumor cells. In a recent Texas A&M VMBS news release tied to a newly published study, the team reported that boosting these microRNAs in lung cancer cell models reduced cancer cell growth by interfering with proteostasis, the systems cells use to make, fold, and clear proteins. The work comes from Peter Nghiem and colleagues in Texas A&M’s Department of Veterinary Integrative Biosciences and was published in a peer-reviewed paper this spring. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, this is another example of how comparative and translational oncology research inside veterinary colleges can shape future cancer therapeutics well beyond traditional cytotoxic approaches. MicroRNA-based strategies aim to reset dysregulated gene networks rather than simply destroy rapidly dividing cells, which could eventually matter for both human and animal oncology if delivery, safety, and tumor targeting can be solved. The findings are still preclinical, but they reinforce the growing role of veterinary research environments in uncovering mechanism-based cancer targets. (pmc.ncbi.nlm.nih.gov)
What to watch: The next key step will be whether the team or outside groups can translate these cell-level findings into effective in vivo delivery and, eventually, therapeutic testing. (pmc.ncbi.nlm.nih.gov)
Key facts
- Study type
- Preclinical study in non-small cell lung cancer cell models
- MicroRNAs studied
- miR-15a and miR-16
- Main finding
- Boosting miR-15a and miR-16 reduced cancer cell growth
- Proposed mechanism
- Interfered with proteostasis, the cell protein-handling system
- Research team
- Peter Nghiem and colleagues at Texas A&M
- Institution
- Texas A&M College of Veterinary Medicine & Biomedical Sciences
- Publication status
- Published in a peer-reviewed paper this spring
- Cancer type
- Non-small cell lung cancer
Texas A&M researchers are spotlighting a new way to slow non-small cell lung cancer, centering on two naturally occurring microRNAs, miR-15a and miR-16, that appear to suppress tumor growth by restoring normal cellular regulation. The work, highlighted by the Texas A&M College of Veterinary Medicine & Biomedical Sciences and published recently in a peer-reviewed study, points to a therapeutic strategy built around genetic control rather than direct tumor destruction. (pmc.ncbi.nlm.nih.gov)
The research builds on a long-running scientific story around miR-15a and miR-16. These microRNAs have been studied for years as tumor suppressors in multiple cancers, including lung cancer, and earlier work showed they are often deleted or downregulated in non-small cell lung cancer and can influence core cell-cycle regulators. Texas A&M’s new contribution adds a more specific mechanistic angle by examining how the pair affects proteostasis, the internal protein-handling machinery cancer cells rely on to sustain growth. (aacrjournals.org)
According to the study, the investigators tested the effect of miR-15a and miR-16 in non-small cell lung cancer models and found that restoring their expression significantly curtailed cancer cell growth. The paper frames the mechanism around disruption of proteostasis and the broader anabolic machinery that tumors use to maintain malignant behavior. That matters because non-small cell lung cancer accounts for the large majority of lung cancer cases, and resistance to standard therapies continues to drive demand for more targeted approaches. (pmc.ncbi.nlm.nih.gov)
Texas A&M’s involvement also reflects the increasingly translational scope of veterinary biomedical research. Peter Nghiem, an associate professor in the Texas A&M College of Veterinary Medicine & Biomedical Sciences, has been involved in other regenerative and molecular research efforts at the institution, underscoring how veterinary research settings are contributing to platform technologies with broader oncology relevance. While the available coverage around this study appears to come primarily from Texas A&M and the paper itself, the underlying concept fits a wider industry push toward RNA-based therapeutics and more precise biologic interventions. (vetmed.tamu.edu)
Expert commentary directly tied to this paper was limited in publicly available coverage, but the broader field has consistently viewed miR-15a/16 as promising therapeutic candidates because they regulate multiple cancer-related pathways at once. That multi-target effect is part of the appeal, especially in cancers like non-small cell lung cancer where tumor cells can adapt around single-pathway drugs. At the same time, published background from Texas A&M medical researchers has noted a central hurdle: turning microRNA biology into treatment depends on solving delivery. (jmsgr.tamhsc.edu)
Why it matters: For veterinary professionals, this is useful less as an immediate clinical development and more as a signal about where oncology research is moving. Veterinary schools are increasingly part of the discovery pipeline for RNA therapeutics, gene regulation research, and comparative oncology. If microRNA-based therapies become practical, they could eventually influence how clinicians think about cancer management across species, especially for tumors where conventional surgery, radiation, or chemotherapy offer limited control or substantial adverse effects. The study also reinforces a familiar lesson in translational medicine: advances in molecular oncology often begin with mechanism, then spend years moving through delivery, safety, and efficacy testing before they reach practice. (vetmed.tamu.edu)
What to watch: The near-term questions are whether these findings can be replicated in animal models, what delivery system could carry miR-15a and miR-16 into tumors effectively, and whether Texas A&M or collaborators move toward patenting, licensing, or follow-on translational studies. Until then, the work stands as an early but credible marker of how veterinary biomedical research is contributing to next-generation cancer therapy discovery. (pmc.ncbi.nlm.nih.gov)